MPV and NLR as Predictors of SBP Diagnosis

Sponsor
Sohag University (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04775420
Collaborator
(none)
200
5

Study Details

Study Description

Brief Summary

The aim of the study is to investigate the clinical utility of mean platelet volume (MPV) and neutrophil to lymphocyte ratio (NLR) as diagnostic markers for spontaneous bacterial peritonitis (SBP).

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Mean Platelet Volume (MPV) and Neutrophil to Lymphocyte Ratio (NLR) as Predictors of Spontaneous Bacterial Peritonitis in Cirrhotic Patients
Anticipated Study Start Date :
Mar 1, 2021
Anticipated Primary Completion Date :
May 31, 2021
Anticipated Study Completion Date :
Jul 31, 2021

Arms and Interventions

Arm Intervention/Treatment
Group 1

Ascetic patients without spontaneous bacterial peritonitis

Diagnostic Test: Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)
MPV and NLR are easily accessible and inexpensive tests

Group 2

Ascetic patients with spontaneous bacterial peritonitis

Diagnostic Test: Measurement of mean platelet volume (MPV) and blood neutrophil to lymphocyte ratio (NLR)
MPV and NLR are easily accessible and inexpensive tests

Outcome Measures

Primary Outcome Measures

  1. The utility of MPV as non-invasive predictor of SBP [1 year]

    It will be measured from CBC

  2. The utility of NLR as non-invasive predictor of SBP [1 year]

    It will be measured from CBC

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Decompensated liver cirrhosis ascetic patients.
Exclusion Criteria:
  • Immunocompromised patients.

  • Patients who had received antibiotics before hospital admission.

  • Patients on anticoagulant medications, NSAIDs, or oral contraceptive drugs.

  • Patients with heart failure, diabetes mellitus, hypertension, hyperlipidemia, peripheral vascular disease, hematological disorders, and neoplastic disorders and patients with clinically overt hypothyroidism or hyperthyroidism or with clinically and laboratory-evident autoimmune diseases.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Sohag University

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ahmed Abudeif Abdelaal, MD, Principal Investigator, Sohag University
ClinicalTrials.gov Identifier:
NCT04775420
Other Study ID Numbers:
  • Soh-Med-21-02-22
First Posted:
Mar 1, 2021
Last Update Posted:
Mar 3, 2021
Last Verified:
Feb 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ahmed Abudeif Abdelaal, MD, Principal Investigator, Sohag University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 3, 2021